You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Generation of Human Hepatocytes

    SBC: IN VIVO TECHNOLOGIES            Topic: N/A

    DESCRIPTION (provided by applicant): The goal of this project is to produce "humanized" livers in large animal models such as sheep and pigs that can serve as a reliable source of significant numbers of functional human hepatocytes. The isolated human hepatocytes and/or "humanized" livers can be used for drug toxicity studies as well as for possible clinical use in patients with liver failure. Tra ...

    STTR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health
  2. STTR Phase I: Local Vapor Fuel Cell

    SBC: NANOTEK INSTRUMENTS INC            Topic: N/A

    This Small Business Technology Transfer Research (STTR) Phase I proposal will overcome the most critical problems associated with the construction of a direct methanol fuel cell (DMFC): complex, bulky and heavy cell structures, low fuel efficiency, and high cost. These issues have severely impeded the successful commercialization of DMFCs for powering portable electronic devices. A commercially vi ...

    STTR Phase I 2004 National Science Foundation
  3. Chip-to-Chip Optical Interconnects Using Photonic Crystal Emitters and Waveguides

    SBC: OPTICOMP CORP.            Topic: AF03T021

    The goal of this proposed Phase I STTR effort is to demonstrate the feasibility of incorporating photonic crystal (PC) technology within OCC's existing optoelectronic module technology. This will be accomplished through the design and modeling of PC light emitters and waveguides, as well as characterization of their coupling behavior with external systems. The utilization of nanoscale PC technol ...

    STTR Phase I 2004 Department of DefenseAir Force
  4. Plasma Diagnostic for Alzheimer's Disease Pathology

    SBC: SAMARITAN PHARMACEUTICALS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Presently, there exists no simple minimally invasive test, such as a blood test, that can differentiate patients affected by Alzheimer's disease (AD) from healthy individuals. Our long-term goal is to develop new strategies for determining prognosis or predicting response to therapy. This will provide tools to improve clinical decision-making in the care of AD ...

    STTR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health
  5. SP004, a sigma-1 ligand with AchE inhibition properties

    SBC: SAMARITAN PHARMACEUTICALS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): The acetylcholinesterase inhibitors (AchEI) are currently the most broadly used drugs to treat AIzheirmer's disease (AD). Unfortunately none of the beneficial effect lasts for more than a short two years time period, probably due to the progressive degeneration of the cholinergic neurons. This indicates that aiming at the same time at another target distinct to ...

    STTR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health
  6. STTR Phase II: Micromachined components for wireless applications

    SBC: LASERLITH CORP.            Topic: ES

    The broader impact/commercialization potential of this project include tunable blocks that would allow a range of spectrally- and spatially-agile devices. These may include high-gain directional antennas that can improve performance while reducing power consumption. The fundamental MEMS varactor technology also offers solutions for critical efficiency and linearity problems as wireless devices emp ...

    STTR Phase II 2014 National Science Foundation
  7. STTR Phase I: Novel Multifunctional, Bio-Based Coupling Agents for Wood Plastic Composites

    SBC: RENUVIX LLC            Topic: CT

    The broader impact/commercial potential of this project involves a significant enhancement in the properties of wood polymer composites (WPCs) by the commercialization of a highly effective bio-based coupling agent made from renewable sources such as plant oils instead of petroleum. By significantly enhancing the properties of WPCs, substantial benefit to society will result by providing new appli ...

    STTR Phase I 2014 National Science Foundation
  8. Prediction and Measurement of the Carbon Build-Up in Film-Cooled Rocket Engines

    SBC: SIERRA ENGINEERING, INC.            Topic: AF15AT21

    ABSTRACT: Sierra Engineering Inc. (Sierra) believes that existing chemical kinetic models can be efficiently incorporated into commercial CFD codes to predict the mixing, pyrolysis, soot formation and carbon deposition within film cooled rocket engines. During this Phase I STTR effort we will demonstrate that this analysis capability is practical and that we can generate appropriate model validati ...

    STTR Phase I 2015 Department of DefenseAir Force
  9. Galectin 1: A novel small protein therapy for Duchenne muscular dystrophy

    SBC: STRYKAGEN CORPORATION            Topic: NIAMS

    DESCRIPTION provided by applicant Duchenne Muscular Dystrophy DMD is a fatal muscle disease affecting in every male births DMD results from mutations in the gene encoding the dystrophin a kDa scaffolding protein responsible for providing a mechanical link between the muscle fiber actin cytoskeleton and a transmembrane protein complex called the dystrophin associated glycoprotein ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  10. Optimization of an integrin enhancing molecule for the treatment of Duchenne muscular dystrophy

    SBC: STRYKAGEN CORPORATION            Topic: NIAMS

    DESCRIPTION provided by applicant Duchenne muscular dystrophy is caused by mutations in the dystrophin gene resulting in the loss of the dystrophin glycoprotein complex in skeletal muscle Loss of dystrophin results in reduced sarcolemmal integrity progressive muscle damage and compromised muscle function There is currently no cure and limited treatment options for DMD and all affected child ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government